Infacol

Simeticone, the active ingredient in Infacol, is an antiflatulent presented as a 40 mg/5 mL oral suspension for oral use. It relieves infant colic, gas, bloating and flatulence by facilitating the removal of trapped gas in the gastrointestinal tract in infants and young children, under medical guidance.

GNH USA supplies Infacol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for bulk and individual orders across global markets.

Infacol (simeticone) is used to alleviate gastrointestinal gas‑related conditions in infants and young children.

- Infant colic: reduces discomfort and crying by helping trapped gas bubbles coalesce and be expelled from the digestive tract. - Gas and bloating: eases abdominal distension and pressure, improving feeding tolerance and sleep in affected infants. - Flatulence: lessens the frequency and intensity of passing gas, supporting overall gastrointestinal comfort.

Simeticone is generally well tolerated, but some users may experience mild or rare adverse reactions.

Common Side Effects: - Mild gastrointestinal upset: occasional stomach discomfort or mild cramping. - Transient diarrhea: brief episodes of loose stools. - Nausea: feeling of queasiness without vomiting. - Vomiting: occasional expulsion of stomach contents. - Mild skin rash: localized redness or itching at the site of contact.

Serious or Rare Side Effects: - Allergic reaction: signs such as hives, swelling, or difficulty breathing. - Severe skin eruption: conditions like Stevens‑Johnson syndrome. - Respiratory distress: unexpected breathing difficulties requiring medical attention.

When using Infacol, consider the following precautions to ensure safe and effective use.

- Age restriction: intended for infants and young children as directed by a healthcare professional. - Allergy check: avoid if the child has known hypersensitivity to simeticone or any formulation excipients. - Underlying conditions: consult a physician if the infant has persistent vomiting, gastro‑oesophageal reflux, or other gastrointestinal disorders. - Concomitant medicines: inform the healthcare provider of all current medications, including over‑the‑counter products. - Pregnancy and lactation: safety has not been established; use only if clearly needed and advised by a clinician. - Store at ambient temperature: keep below 25 °C, retain in the original container, and protect from moisture and direct sunlight.

Simeticone has minimal systemic absorption, resulting in a low potential for drug interactions, but some considerations are noted.

Major Interactions (Avoid): - None identified: simeticone is not absorbed and does not have clinically significant interactions. - Concurrent use with other antiflatulents: may increase the risk of excessive gas reduction and abdominal discomfort.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may alter gastric acidity, potentially affecting symptom relief; monitor effectiveness. - Antibiotics affecting gut flora: changes in bacterial composition can modify gas production; observe response. - Laxatives: simultaneous use may influence bowel motility, requiring observation for constipation or diarrhea.